Cargando…
Nintedanib and intensive immunosuppressive therapy to treat rapidly progressive interstitial lung disease presenting anti-ARS antibodies
We describe a case of fulminant onset, rapidly progressive-interstitial lung disease (RP-ILD) with anti-ARS antibodies (anti-PL-7). The patient was successfully treated with nintedanib in addition to intensive immunosuppressive therapies, including intravenous cyclophosphamide. Nintedanib has just b...
Autores principales: | Yanagihara, Toyoshi, Suzuki, Kunihiro, Egashira, Ayaka, Ogo, Naruhiko, Asoh, Tatsuma, Nara, Tsukasa, Takatsuki, Kensaku, Yoshizawa, Seiji, Chong, Sy Giin, Hamada, Naoki, Maeyama, Takashige |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7606860/ https://www.ncbi.nlm.nih.gov/pubmed/33163354 http://dx.doi.org/10.1016/j.rmcr.2020.101272 |
Ejemplares similares
-
A Rare Case of Pembrolizumab-Induced Dermatomyositis in a Patient with Cancer of Unknown Primary Origin
por: Takatsuki, Kensaku, et al.
Publicado: (2021) -
Three cases of sequential treatment with nintedanib following pulsed-dose corticosteroids for acute exacerbation of interstitial lung diseases
por: Nakashima, Kazuki, et al.
Publicado: (2021) -
A Case of Drug-Induced Interstitial Lung Disease Caused by Epirubicin and Cyclophosphamide Therapy Before Breast Cancer Surgery
por: Egashira, Ayaka, et al.
Publicado: (2021) -
A fatal case of diffuse alveolar hemorrhage complicated by rheumatoid arthritis
por: Nakashima, Kazuki, et al.
Publicado: (2021) -
Tacrolimus Treatment for Post-COVID-19 Interstitial Lung Disease
por: Ohgushi, Migiwa, et al.
Publicado: (2021)